Intel applies nanotechnology expertise to disease detection:
This article was originally published in Clinica
Executive Summary
Intel has teamed up with a US institution to apply its expertise in nanotechnology to develop improved methods of studying, diagnosing and preventing cancer. The company is building an Intel Raman bioanalyser system at the Fred Hutchinson Cancer Research Center, in Seattle, to determine whether the technology, previously used to detect microscopic imperfections on silicon chips, can also detect subtle traces of disease. The instrument beams lasers onto medical samples, such as serum, to create images that reveal the chemical structure of molecules. The research could lead to a new era of molecular diagnostics and improved methods of early disease detection, the company said.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.